PROTOCOLOS CLÍNICOS E DIRETRIZES TERAPÊUTICAS

Protocolos Clínicos e Diretrizes Terapêuticas 8. Alem AM, Sherrard DJ, Gillen DL, Weiss NS, Beresford SA, Heckbert SR, et al. Increased risk of hip fracture among patients with end-stage renal disease. Kidney Int. 2000;58(1):396-9. 9. Stehman-Breen CO, Sherrard DJ, Alem AM, Gillen DL, Heckbert SR, Wong CS, et al. Risk factors for hip fracture among patients with end-stage renal disease. Kidney Int. 2000;58(5):2200-5. 10. Mittalhenkle A, Gillen DL, Stehman-Breen CO. Increased risk of mortality associated with hip fracture in the dialysis population. Am J Kidney Dis. 2004;44(4):672-9. 11. Sociedade Brasileira de Nefrologia (SBN). Censo de Diálise SBN 2008 [Internet]. São Paulo: SBN; 2008 [citado 2009 Out 30]; Disponível em: http://198.106.86.84/Censo/2008/censoSBN2008.pdf 12. Araujo SM, Ambrosoni P, Lobão RR, Caorsi H, Moysés RM, Barreto FC, et al. The renal osteodystrophy pattern in Brazil and Uruguay: an overview. Kidney Int Suppl. 2003;(85):S54-6. 13. Norman ME, Mazur AT, Borden S 4th, Gruskin A, Anast C, Baron R, et al. Early diagnosis of juvenile renal osteodystrophy. J Pediatr. 1980;97(2):226-32. 14. Levin A, Bakris GL, Molitch M, Smulders M, Tian J, Williams LA, et al. Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease. Kidney Int. 2007;71(1):31-8. Epub 2006 Nov 8. 15. Vassalotti JA, Uribarri J, Chen SC, Li S, Wang C, Collins AJ, et al. Trends in mineral metabolism: Kidney Early Evaluation Program (KEEP) and the National Health and Nutrition Examination Survey (NHANES) 1999-2004. Am J Kidney Dis. 2008;51(4 Suppl 2):S56-68. 16. Moe SM. Management of renal osteodystrophy in peritoneal dialysis patients. Perit Dial Int. 2004;24(3):209-16. 17. Gal-Moscovici A, Popovtzer MM. New worldwide trends in presentation of renal osteodystrophy and its relationship to parathyroid hormone levels. Clin Nephrol. 2005;63(4):284-9. 18. Ureña P, Hruby M, Ferreira A, Ang KS, de Vernejoul MC. Plasma total versus bone alkaline phosphatase as markers of bone turnover in hemodialysis patients. J Am Soc Nephrol. 1996;7(3):506-12. 19. National Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis. 2003;42(4 Suppl 3):S1-201. 20. D’HaesePC, CouttenyeMM, GoodmanWG, LemoniatouE, Digenis P, Sotornik I, et al. Use of the low-dose desferrioxamine test to diagnose and differentiate between patients with aluminium-related bone disease, increased risk for aluminium toxicity, or aluminium overload. Nephrol Dial Transplant. 1995;10(10):1874-84. 21. Barata JD, D’Haese PC, Pires C, Lamberts LV, Simões J, De Broe ME. Low-dose (5 mg/kg) desferrioxamine treatment in acutely aluminium-intoxicated haemodialysis patients using two drug administration schedules. Nephrol Dial Transplant. 1996;11(1):125-32. 22. Maffessoni R, Sander GB, Picon PD, Amaral KM, Krug BC, Manfro RC. Hiperfosfatemia na insuficiência renal crônica. In: Picon PD, Beltrame A, editores. Protocolos clínicos e diretrizes terapêuticas. Brasília: Ministério da Saúde; 2002. p. 455-60. 23. Saraiva GL, Cendoroglo MS, Ramos LR, Araújo LM, Vieira JG, Kunii I, et al. Influence of ultraviolet radiation on the production of 25 hydroxyvitamin D in the elderly population in the city of São Paulo (23 degrees 34’S), Brazil. Osteoporos Int. 2005;16(12):1649-54. Epub 2005 Jun 10. 24. Nordal KP, Dahl E. Low dose calcitriol versus placebo in patients with predialysis chronic renal failure. J Clin Endocrinol Metab. 1988;67(5):929-36. 25. Hamdy NA, Kanis JA, Beneton MN, Brown CB, Juttmann JR, Jordans JG, et al. Effect of alfacalcidol on natural course of renal bone disease in mild to moderate renal failure. BMJ. 1995;310(6976):358-63. 26. Barreto FC, Barreto DV, Moyses RM, Neves KR, Canziani ME, Draibe SA, et al. K/DOQI-recommended intact PTH levels do not prevent low-turnover bone disease in hemodialysis patients. Kidney Int. 2008;73(6):771-7. Epub 2008 Jan 9. 27. Baker LR, Muir JW, Sharman VL, Abrams SM, Greenwood RN, Cattell WR, et al. Controlled trial of calcitriol in hemodialysis patients. Clin Nephrol. 1986;26(4):185-91. 28. Palmer SC, McGregor DO, Macaskill P, Craig JC, Elder GJ, Strippoli GF. Meta-analysis: vitamin D compounds in chronic kidney disease. Ann Intern Med. 2007;147(12):840-53. 29. Tonelli M. Vitamin D in patients with chronic kidney disease: nothing new under the sun. Ann Intern Med. 2007;147(12):880-1. 30. Quarles LD, Yohay DA, Carroll BA, Spritzer CE, Minda SA, Bartholomay D, et al. Prospective trial of pulse oral versus intravenous calcitriol treatment of hyperparathyroidism in ESRD. Kidney Int. 1994;45(6):1710-21. 31. Cruz DN, Perazella MA. Biochemical aberrations in a dialysis patient following parathyroidectomy. Am J Kidney Dis. 1997;29(5):759-62. 32. Sampaio E, Moyses RM. Paratireoidectomia na DRC. J Bras Nefrol. 2008;30(Suppl 2):27-9. 33. Clair F, Leenhardt L, BourdeauA, Zingraff J, Robert D, Dubost C, et al. Effect of calcitriol in the control of plasma calcium after parathyroidectomy. A placebo-controlled, double-blind study in chronic hemodialysis patients. Nephron. 1987;46(1):18-22. 496